Samsung Biologics to Present Organoid-Based Research Platform at AACR Annual Meeting 2026
Samsung Biologics will participate in the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from April 17 to 22 in San Diego, California. The event is recognized as one of the world’s most prominent oncology gatherings, bringing together researchers, clinicians, and industry leaders to share the latest advances across the cancer research continuum, from discovery science to clinical development.
At this year’s event, the company will showcase its research capabilities in early discovery and drug screening through both speaking and poster sessions. The speaking session will focus on the application of its patient-derived organoids platform, Samsung Organoids, which supports more informed decision-making in oncology research and early development. Additional data from the poster session will demonstrate how the platform can enhance translational accuracy and accelerate therapeutic discovery alongside S-Dual®, the company’s bispecific antibody platform, to support the advancement of next-generation therapeutic programs.
Through its participation, Samsung Biologics will engage with the global industry professionals and contribute to ongoing discussions on next-generation oncology solutions. The company aims to expand its research capabilities and support the development of innovative therapies, while strengthening collaboration with partners across the healthcare industry.
Samsung Biologics will participate in the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from April 17 to 22 in San Diego, California. The event is recognized as one of the world’s most prominent oncology gatherings, bringing together researchers, clinicians, and industry leaders to share the latest advances across the cancer research continuum, from discovery science to clinical development.
At this year’s event, the company will showcase its research capabilities in early discovery and drug screening through both speaking and poster sessions. The speaking session will focus on the application of its patient-derived organoids platform, Samsung Organoids, which supports more informed decision-making in oncology research and early development. Additional data from the poster session will demonstrate how the platform can enhance translational accuracy and accelerate therapeutic discovery alongside S-Dual®, the company’s bispecific antibody platform, to support the advancement of next-generation therapeutic programs.
Through its participation, Samsung Biologics will engage with the global industry professionals and contribute to ongoing discussions on next-generation oncology solutions. The company aims to expand its research capabilities and support the development of innovative therapies, while strengthening collaboration with partners across the healthcare industry.
Share article
Related Content